Skip to main content

Table 2 Ethnic differences in diarrheal side effects in respondents switching from BID SGCs to BID tablets

From: Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules

 

BID Respondents (n = 332)

White (n = 136)

Black (n = 123)

Hispanic (n = 67)

Relative Risk (Tablets vs. SGCs)

Antidiarrheal use (more than "rarely use")

0.73*

0.72*

0.95

0.65

Diarrhea frequency 3+ per week

0.60*

0.68*

0.52*

0.39*

Respondent self-defined "severe" diarrhea

0.28*

0.47*

0.13*

0.17*

Proportion of respondents (Tablets vs. SGCs)

Respondent self-defined "severe" diarrhea

3.3% vs. 11.7%*

7% vs. 15%*

1% vs. 8%*

2% vs. 12%*

  1. * p < 0.05
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us